Proteomic Signatures of Vemurafenib Resistance in Canine Urothelial Carcinoma Harboring the BRAFV595E Mutation
Journal of Proteome Research · 07.08.2026 · 25 (8) · 4262-4275
DOI: 10.1021/acs.jproteome.6c00246 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Proteome Research, online erschienen am 26.06.2026. Verfasst von Rodrigo Mohallem und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Comparative Pathobiology, College of Veterinary Medicine, Purdue University, West Lafayette, Indiana47907, United States. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins B-raf, Drug Resistance, Neoplasm, Dog Diseases, Indoles. Die Arbeit nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Purdue University, Indiana Clinical and Translational Science Institute.
Abstract (Originalsprache)
Naturally occurring canine invasive urothelial carcinoma (InvUC) often harbors a BRAFV595E mutation, analogous to human BRAFV600E found across multiple cancer types, and has been used to investigate the effects of BRAF-targeted therapy. To investigate proteomic and phosphoproteomic changes during therapy, we analyzed 42 samples from 14 dogs with BRAFV595E-positive InvUC treated with vemurafenib. Tumors were collected via cystoscopy before treatment (Pre-Vem), 1 month into treatment (Vem-1-month), and at the time of progressive disease (Vem-PD). We observed consistent early suppression of proteins and phosphosites in tumors after 1 month of vemurafenib treatment in dogs that responded to the treatment, followed by their rebound at the time of progressive disease, highlighting early tumor suppressive events that are later reversed as tumors adapt and develop resistance. Key pathways affected included "positive regulation of telomerase assembly and localization to Cajal body", "positive regulation of protein localization to telomere", and "positive regulation of protein localization to Cajal body". Additionally, consistent "Rho GTPase signaling" changes were observed across both proteomic and phosphoproteomic analyses, underscoring the functional reactivation of this pathway in resistant tumors. In summary, these findings reveal molecular signatures of early response and acquired resistance to vemurafenib and offer a valuable resource for future investigation of BRAF-targeted therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Comparative Pathobiology, College of Veterinary Medicine, Purdue University, West Lafayette, Indiana47907, United States.
- Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Purdue University, West Lafayette, Indiana47907, United States.
- Purdue University Institute for Cancer Research, West Lafayette, Indiana47907, United States.
ORCID-Profile: Rodrigo Mohallem, Uma K Aryal
Förderung
- Purdue University
- Indiana Clinical and Translational Science Institute
Zitieren
APA
Mohallem, R., Dhawan, D., Enstrom, A. W., Knapp, D. W., & Aryal, U. K. (2026). Proteomic Signatures of Vemurafenib Resistance in Canine Urothelial Carcinoma Harboring the BRAFV595E Mutation. Journal of Proteome Research, 25(8), 4262-4275. https://doi.org/10.1021/acs.jproteome.6c00246
Vancouver
Mohallem R, Dhawan D, Enstrom AW, Knapp DW, Aryal UK. Proteomic Signatures of Vemurafenib Resistance in Canine Urothelial Carcinoma Harboring the BRAFV595E Mutation. Journal of Proteome Research. 2026;25(8):4262-4275. doi:10.1021/acs.jproteome.6c00246
BibTeX
@article{Mohallem2026,
author = {Mohallem, Rodrigo and Dhawan, Deepika and Enstrom, Alexander W and Knapp, Deborah W and Aryal, Uma K},
title = {Proteomic Signatures of Vemurafenib Resistance in Canine Urothelial Carcinoma Harboring the BRAFV595E Mutation},
journal = {Journal of Proteome Research},
year = {2026},
volume = {25},
number = {8},
pages = {4262--4275},
doi = {10.1021/acs.jproteome.6c00246}
}
EUVIMED